Tech Company M&A Transactions
Tularik Acquisition
Tularik, operating out of South San Francisco, was acquired by Amgen. The transaction price was $1.3 billion.
Transaction Overview
Company Name
Acquired By
Announced On
3/29/2004
Transaction Type
M&A
Amount
$1,300,000,000
M&A Terms
Under the terms of the agreement, Amgen, in a tax-free transaction, will exchange Tularik common stock for Amgen common stock in a ratio that fixes Tularik's value at $25 per share based on the average Amgen stock price during a set number of trading days prior to the close of the transaction. The value of the transaction as of the anticipated closing date is expected to be approximately $1.3 billion, net of estimated cash to be acquired and net of Amgen's existing ownership of Tularik of approximately 21 percent. In addition, there will be a one-time charge related to in-process research and development affecting GAAP earnings per share in the period during which the deal closes.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
1120 Veterans Blvd
South San Francisco, CA 94080
USA
South San Francisco, CA 94080
USA
Phone
Website
Email Address
Not Recorded
Overview
Tularik has research alliances with Medarex to develop cancer therapies and with the drug division of Japan Tobacco to develop drugs for metabolic diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Goeddel
Browse more venture capital transactions:
Prev: 3/24/2004: A&G Pharmaceutical venture capital transaction
Next: 3/29/2004: Cobalt venture capital transaction
Share this article
News on VC Transactions
We do our best to record every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs